Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34856725)
Watch
English
Secondary hormonal therapies in the treatment of prostate cancer.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
Secondary hormonal therapies in the treatment of prostate cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
main subject
prostate cancer
1 reference
based on heuristic
inferred from title
author
William K. Oh
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
author name string
William K OH
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
retrieved
4 August 2017
language of work or name
English
0 references
publication date
1 September 2002
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
published in
Urology
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
volume
60
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
page(s)
87-92; discussion 93
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
issue
3 Suppl 1
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
cites work
Cancer statistics, 2001
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Secondary hormonal manipulations in hormone refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PC-SPES: current evidence and remaining questions
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo .
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901581-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0090-4295(02)01581-9
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
PubMed ID
12231058
1 reference
stated in
Europe PubMed Central
PubMed ID
12231058
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12231058%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
